1.Chemical constituents from marine alga Chaetomorpha basiretorsa.
Da-yong SHI ; Li-jun HAN ; Jie SUN ; Ying WANG ; Yong-chun YANG ; Jian-gong SHI ; Xiao FAN
China Journal of Chinese Materia Medica 2005;30(5):347-350
OBJECTIVETo investigate the chemical constituents of marine alga Chaetomorpha basiretorsa.
METHODCompounds were isolated by normal phase silica gel and Sephadex LH-20 gel colum chromatography, reverse phase MPLC, reverse phase HPLC and recrystallization. Their structures were elucidated by spectroscopic methods including MS, IR, NMR, and X-ray crystalography. Cytotoxicity of the compounds were screened by using standard MTT method.
RESULTNine compounds were isolated from C. basiretorsa and their structures were identified as N-phenyl-2-naphthalenamine( I ), dibutyl phthalate( II ), diisobutyl phthalate( III ), 1-phenyl-ethane-1, 2-diol( IV ), 2-hydrox-gamma-benzaldehyde( V ), diethyleneglycol monobenzoate( VI ), uracil( VII ), thymine( VIII ) and thymidine( IX ).
CONCLUSIONAll these compounds were obtained from this genus for the first time, N-phenyl-2-naphthalenamine and diethyleneglycol monobenzoate were first reported from the marine organisms. Compound I and VII showed moderate activity against KB cell(IC50 10.15 microg x mL(-1) for I and 3.79 microg x mL(-1) for VII ) and MCF-7 cell(IC50 3.24 microg x mL(-1) for VII).
1-Naphthylamine ; analogs & derivatives ; chemistry ; isolation & purification ; Chlorophyta ; chemistry ; Crystallization ; Humans ; KB Cells ; drug effects ; Uracil ; chemistry ; isolation & purification ; pharmacology
2.Hyperamylasemia Related to Sertraline.
Mehmet Emin CEYLAN ; Alper EVRENSEL ; Barış ÖNEN ÜNSALVER
Korean Journal of Family Medicine 2016;37(4):259-259
No abstract available.
Hyperamylasemia*
;
Sertraline*
3.The Therapeutic Effect of Sertraline in Treatment-resistant Schizophrenics.
Korean Journal of Psychopharmacology 1997;8(1):69-78
OBJECT: This study was undertaken to know whether there is any therapeutic effecets of sertraline in treatment-resistant schizophrenics. METHOD: Seventy seven treatment-resistant schizophrenic patients, to whom the same antipsychotics as usual were administered, were randomly assigned to two groups; to the experimental group, sertraline was and to the controlled group, placebo was administered adjuntively for 6weeks in single blind design. We assessed psychopathology by BPRS, PANSS, YBOCS, HRSD, and SCL-90-R. RESULTS: BPRS, positive scale of PANSS, and HRSD were significantly decreased in experimental group and statistically siginificant differences between the experimental group and placebo group. Negative scale of PANSS and YBOCS were significantly decresed in experimental group but no statistically significant differences between the experimental group and placebo group. The therapeutic effect of sertraline was occurred within 3rd weeks. CONCLUSION: We suggested that sertraline may be useful in the treatment of schizophrenic symtom in treatment-resistent schizophrenia, especially in positive and depressive symptoms.
Antipsychotic Agents
;
Depression
;
Humans
;
Psychopathology
;
Schizophrenia
;
Sertraline*
4.Adjuvant Sertraline Treallnent for Chronic Schizophrenia :A Randomized, Double Blind, Placeho-Controlled Study.
Min Soo LEE ; Yong Ku KIM ; Sang Kyu LEE ; Kwang Yoon SUH
Journal of the Korean Society of Biological Psychiatry 1997;4(1):127-131
OBJECTIVE: To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study. METHOD: Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen, Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6 and 8 weeks of treatment. RESULTS: The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI and S-A scale scores at any between sertraline and placebo treatment. CONCLUSION: This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.
Haloperidol
;
Hospitalization
;
Humans
;
Inpatients
;
Schizophrenia*
;
Sertraline*
5.Antidepressant and the Quality of Life of Depressive Patient.
Journal of the Korean Society of Biological Psychiatry 1997;4(1):116-120
This study investigated the antidepressant efficacy and it's impact on the quality of life of depressed patients. We performed Hamilton Depression Rating Scale(HDRS), and Montgomery-Asberg Depression Rating Scale(MADRS), and Health-related Quality of Life Questionnaire(HQLQ) to both tricyclic antidepressant(TCA) and sertraline groups. There were 16 subjects in the study. The tricyclic group had 9 subjects and the sertraline group had 7. The TCA and sertraline produced a similar degree of response. Both groups experienced a reduction of 70% or more in mean HDRS and MADRS total score after 6wks. In HQLQ, the TCAs group also showed improved bed disability days, alertness behavior, and social interaction, the sertraline group showed improved health perception, alertness behavior, home management, and social interaction. We suggested that the improvement of "Quality of life" were not in proportion to the clinical symptom's improvement. Therefore, clinicians should consider the benefit of antidepressant treatment in terms of quality of life.
Depression
;
Humans
;
Interpersonal Relations
;
Quality of Life*
;
Sertraline
6.Effects of Sertraline on the 1% Sucrose Consumption and the Body Weight Following Chronic Unpredictable Mild Stress in Rats.
Gi Chul LEE ; Sunyoung CHO ; Jung Ho LEE ; Hyun Taek KIM
Journal of Korean Neuropsychiatric Association 1998;37(1):159-167
The study was designed to evaluate the effects of sertraline on l% sucrose intake and weight change in rats with chronic unpredictable mild stress and normal controls. We applied 11 types of stress regimens and identified depressive behaviours in 18 Spraque-Dawley rats for 8 weeks. After 4 weeks of chronic unpredictable mild stress procedure, those 18 rats were stratified into a sertraline-treated subgroup and a saline subgroup. Also nonstressed 18 rats were stratified into the sertraline-treated subgroup and the saline subgroup and were started intraperitoneal injections of sertraline(4.29mg/Kg) or saline for rest of 4 weeks. The 1% sucrose intake and the body weight were checked on the 4th day of every week, over the 8 weeks of experiment. The results were as follows: 1) The sertraline-treated subgroup of chronic unpredictable mild stressed rats showed significant increase of 1% sucrose intake between the 1st week and the 2nd, the 3rd and 4th week, while the sertraline-treated subgroup of non-stressed rats showed decreasing trend for 1% sucrose intake. 2) The sertraline-treated subgroup of chronic unpredictable mild-stressed rats showed a sustained decrease of body weight, while the sertraline-treated subgroup of non-stressed rats showed a non-significant increase of body weight. 3) In the group subjected to chronic unpredictable mild stress, there were no significant correlations between 1% sucrose intake and body weight and also no correlations in the nonstressed group. In summary, sertraline had an effect on restoring the decreased 1% sucrose intake to normal condition but no effect on regaining the body weight in the chronic unpredictable mild stresstreated rats. Sertraline resulted in a decrease of l% sucrose intake and no effect on body weight in the non-stressed rats.
Animals
;
Body Weight*
;
Injections, Intraperitoneal
;
Rats*
;
Sertraline*
;
Sucrose*
7.Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder.
Woo Young JUNG ; Sae Heon JANG ; Sung Gon KIM ; Young Myo JAE ; Bo Geum KONG ; Ho Chan KIM ; Byeong Moo CHOE ; Jeong Gee KIM ; Choong Rak KIM
Psychiatry Investigation 2016;13(4):440-446
OBJECTIVE: The aim of the present study was to investigate differences in discontinuation time among antidepressants and total antidepressant discontinuation rate of patients with depression over a 6 month period in a naturalistic treatment setting. METHODS: We reviewed the medical records of 900 patients with major depressive disorder who were initially prescribed only one kind of antidepressant. The prescribed antidepressants and the reasons for discontinuation were surveyed at baseline and every 4 weeks during the 24 week study. We investigated the discontinuation rate and the mean time to discontinuation among six antidepressants groups. RESULTS: Mean and median overall discontinuation times were 13.8 and 12 weeks, respectively. Sertraline and escitalopram had longer discontinuation times than that of fluoxetine, and patients who used sertraline discontinued use significantly later than those taking mirtazapine. No differences in discontinuation rate were observed after 24 weeks among these antidepressants. About 73% of patients discontinued antidepressant treatment after 24 weeks. CONCLUSION: Sertraline and escitalopram tended to have longer mean times to discontinuation, although no difference in discontinuation rate was detected between antidepressants after 24 weeks. About three-quarters of patients discontinued antidepressant maintenance therapy after 24 weeks.
Antidepressive Agents*
;
Citalopram
;
Depression
;
Depressive Disorder, Major*
;
Fluoxetine
;
Humans
;
Medical Records
;
Sertraline
8.Effect of Sertraline on the Regulation of Serotonin Transporter mRNA Levels in Rat Brain.
Chang Yoon KIM ; Seong Yoon KIM ; Jin Pyo HONG ; Chul LEE ; On You HWANG ; Oh Su HAN
Journal of Korean Neuropsychiatric Association 1999;38(5):1071-1076
The knowledge of gene regulation of serotonin transporter mRNA may provide clues to understanding how antidepressants affect their therapeutic actions. Recently, the effects of antidepressants on the serotonin transporter have been investigated but yielded controversial results. To study this further, we performed in situ hybridization for serotonin transporter mRNA in rats(treatment group, n=5)receiving long term(14 days)treatment with a selective serotonin reuptake inhibiting antidepressant, sertraline(10mg/kg, i.p) Following sertraline treatment, a significant(p<0.05)ncrease in hybridization of serotonin transporter mRNA was observed compared to that observed in vehicle-treated rats(control group, n=5) This result may be interpreted as a compensatory mechanism to reduce synaptic levels of serotonin which were increased by long term sertraline treatment.
Animals
;
Antidepressive Agents
;
Brain*
;
In Situ Hybridization
;
Rats*
;
RNA, Messenger*
;
Serotonin Plasma Membrane Transport Proteins*
;
Serotonin*
;
Sertraline*
9.Effect of Sertraline on Current-Source Distribution of the High Beta Frequency Band: Analysis of Electroencephalography under Audiovisual Erotic Stimuli in Healthy, Right-Handed Males.
Seung Hyun LEE ; Jae Seog HYUN ; Oh Young KWON
Korean Journal of Urology 2010;51(8):550-556
PURPOSE: The purpose of this study was to examine the cerebral changes in high beta frequency oscillations (22-30 Hz) induced by sertraline and by audiovisual erotic stimuli in healthy adult males. MATERIALS AND METHODS: Scalp electroencephalographies (EEGs) were conducted twice in 11 healthy, right-handed males, once before sertraline intake and again 4 hours thereafter. The EEGs included four sessions recorded sequentially while the subjects were resting, watching a music video, resting, and watching an erotic video for 3 minutes, 5 minutes, 3 minutes, and 5 minutes, respectively. We performed frequency-domain analysis using the EEGs with a distributed model of current-source analysis. The statistical nonparametric maps were obtained from the sessions of watching erotic and music videos (p<0.05). RESULTS: The erotic stimuli decreased the current-source density of the high beta frequency band in the middle frontal gyrus, the precentral gyrus, the postcentral gyrus, and the supramarginal gyrus of the left cerebral hemisphere in the baseline EEGs taken before sertraline intake (p<0.05). The erotic stimuli did not induce any changes in current-source distribution of the brain 4 hours after sertraline intake. CONCLUSIONS: It is speculated that erotic stimuli may decrease the function of the middle frontal gyrus, the precentral gyrus, the postcentral gyrus, and the supramarginal gyrus of the left cerebral hemisphere in healthy adult males. This change may debase the inhibitory control of the brain against erotic stimuli. Sertraline may reduce the decrement in inhibitory control.
Adult
;
Brain
;
Cerebrum
;
Electroencephalography
;
Humans
;
Male
;
Music
;
Scalp
;
Serotonin Uptake Inhibitors
;
Sertraline
;
Sexual Behavior
10.A Case with the Syndrome of Inappropriate Antidiuretic Hormone Associated with Sertraline.
Korean Journal of Psychopharmacology 1999;10(1):95-98
Authors report a case of syndrome of inappropriate antidiuretic hormone(SIADH) associated with sertraline. A 77 years-old male patient showed decreased serum & urine osmolality with symptoms of nausea and anorexia after the ingestion of sertraline, 50 mg for four days, which led to the diagnosis of SIADH. The symptoms of nausea and anorexia improved as serum osmolality improved in several days after discontinuation of sertraline. It is recommended to check serum Na level routinely at the initial treatment when patients on SRRI aggrevate in symptom, have a past history of hyponatremia, or are old.
Aged
;
Anorexia
;
Diagnosis
;
Eating
;
Humans
;
Hyponatremia
;
Inappropriate ADH Syndrome
;
Male
;
Nausea
;
Osmolar Concentration
;
Sertraline*